US8124629B2 - Naphthylacetic acids - Google Patents

Naphthylacetic acids Download PDF

Info

Publication number
US8124629B2
US8124629B2 US12/614,478 US61447809A US8124629B2 US 8124629 B2 US8124629 B2 US 8124629B2 US 61447809 A US61447809 A US 61447809A US 8124629 B2 US8124629 B2 US 8124629B2
Authority
US
United States
Prior art keywords
naphthalen
acetic acid
fluoro
methyl
methanesulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US12/614,478
Other languages
English (en)
Other versions
US20100137250A1 (en
Inventor
Fariborz Firooznia
Paul Gillespie
Tai-An Lin
Eric Mertz
Achyutharao Sidduri
Sung-Sau So
Jenny Tan
Kshitij Chhabilbhai Thakkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche Inc filed Critical Hoffmann La Roche Inc
Priority to US12/614,478 priority Critical patent/US8124629B2/en
Publication of US20100137250A1 publication Critical patent/US20100137250A1/en
Application granted granted Critical
Publication of US8124629B2 publication Critical patent/US8124629B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US12/614,478 2008-11-17 2009-11-09 Naphthylacetic acids Expired - Fee Related US8124629B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/614,478 US8124629B2 (en) 2008-11-17 2009-11-09 Naphthylacetic acids

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11514708P 2008-11-17 2008-11-17
US22223509P 2009-07-01 2009-07-01
US12/614,478 US8124629B2 (en) 2008-11-17 2009-11-09 Naphthylacetic acids

Publications (2)

Publication Number Publication Date
US20100137250A1 US20100137250A1 (en) 2010-06-03
US8124629B2 true US8124629B2 (en) 2012-02-28

Family

ID=42062421

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/614,478 Expired - Fee Related US8124629B2 (en) 2008-11-17 2009-11-09 Naphthylacetic acids

Country Status (16)

Country Link
US (1) US8124629B2 (fr)
EP (1) EP2346807A1 (fr)
JP (1) JP2012508715A (fr)
KR (1) KR20110071122A (fr)
CN (1) CN102216249A (fr)
AR (1) AR074353A1 (fr)
AU (1) AU2009315713A1 (fr)
BR (1) BRPI0921254A2 (fr)
CA (1) CA2740864A1 (fr)
IL (1) IL212120A0 (fr)
MX (1) MX2011005200A (fr)
PE (1) PE20110710A1 (fr)
RU (1) RU2011124149A (fr)
TW (1) TWI385145B (fr)
WO (1) WO2010055005A1 (fr)
ZA (1) ZA201102525B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730390A1 (fr) 2008-07-15 2010-01-21 F.Hoffmann-La Roche Ag Acides aminotetrahydroindazoloacetiques
MX2011005120A (es) * 2008-11-17 2011-05-30 Hoffmann La Roche Acidos naftilaceticos.
CA2739725A1 (fr) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Acides naphtylacetiques employes en tant qu'antagonistes ou agonistes partiels de crth2
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
US9000044B2 (en) * 2012-02-28 2015-04-07 Hoffmann-La Roche Inc. Substituted naphthylacetic acids
UY36548A (es) 2015-02-05 2016-06-01 Bayer Cropscience Ag Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas
CN114609263A (zh) * 2021-11-30 2022-06-10 苏州正济药业有限公司 一种(r)-2,4-二碘-3-甲基-1-烯及其对映异构体的检测方法
CN114573557B (zh) * 2022-03-28 2024-03-08 浙江天宇药业股份有限公司 一种奥特康唑的制备方法

Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899529A (en) 1973-02-22 1975-08-12 Merck & Co Inc Aroyl substituted naphthalene acetic acids
US4371537A (en) 1981-08-13 1983-02-01 The Dow Chemical Company Sulfur-substituted phenoxypyridines having antiviral activity
US4443462A (en) 1979-08-06 1984-04-17 Merrell Dow Pharmaceuticals Inc. Antipsychotic 4-(naphthalenyloxy)piperidine derivatives
EP0242518A1 (fr) 1986-02-21 1987-10-28 Bayer Ag Cycloalcano[1,2-b]indole-sulfonamides
EP0253257A2 (fr) 1986-07-16 1988-01-20 Bayer Ag Acides amino-5,6,7,8-tétrahydronaphtyl-oxyacétiques substitués, procédé pour leur fabrication et leur utilisation comme médicaments
EP0405602A1 (fr) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. Dérivés zinciques de substances antiiflammatoires doués d'une activité thérapeutique améliorée
WO1992001675A2 (fr) 1990-07-24 1992-02-06 Rhone-Poulenc Rorer S.A. Composes bis-aryle bicycliques substitues ayant une activite antagoniste selective sur le leukotriene b4, leur preparation et utilisation dans des compositions pharmaceutiques
DE4411856A1 (de) 1993-04-06 1994-10-13 Kao Corp Keratinfaser-Behandlungszusammensetzung
US5424481A (en) 1992-10-19 1995-06-13 Basf Aktiengesellschaft Preparation of methylsulfonylbenzoic acids
EP0657422A1 (fr) 1993-12-09 1995-06-14 Ono Pharmaceutical Co., Ltd. Dérivés de l'acide naphtylacétique comme agonistes et antagonistes de PGEZ
WO2000016798A1 (fr) 1998-09-22 2000-03-30 Curtin University Of Technology Utilisation de composes non-peptidyliques pour le traitement d'affections liees a l'insuline
WO2003028755A1 (fr) 2001-09-28 2003-04-10 Intermune, Inc. Methode de traitement d'une infection par le virus de l'hepatite c chez des patients prealablement traites sans succes
US20050014749A1 (en) 2003-06-20 2005-01-20 Amgen Inc. Piperazine derivatives and methods of use
EP1505061A1 (fr) 2002-05-16 2005-02-09 SHIONOGI & CO., LTD. Compose comprenant un antagonisme du recepteur de pdg2
WO2005040114A1 (fr) 2003-10-14 2005-05-06 Oxagen Limited Composes presentant une activite antagoniste de crth2
WO2005054232A1 (fr) 2003-11-26 2005-06-16 Astrazeneca Ab Acide indole 1-acetique, et derives d'indazole et de benzimidazole utilises pour traiter les troubles respiratoires
WO2006034418A2 (fr) 2004-09-21 2006-03-30 Athersys, Inc. Acides benzimidazole acetiques presentant un antagonisme du recepteur crth2 et utilisations associees
WO2006036664A1 (fr) 2004-09-23 2006-04-06 Amgen Inc. Sulfonamidopropionamides substitues et procedes d'utilisation
US20060154965A1 (en) 2004-12-21 2006-07-13 Harris Ralph N Iii Tetralin and indane derivatives and uses thereof
WO2006091674A1 (fr) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires
WO2007028132A2 (fr) 2005-09-01 2007-03-08 Eli Lilly And Company 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES SUBSTITUEES PAR UN HETEROCYCLE A LIAISON 6-N EN TANT QU'AGONISTES DE RECEPTEUR 5-HT2C
US7226951B2 (en) 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
US20070161698A1 (en) 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
WO2007146136A2 (fr) 2006-06-12 2007-12-21 Merck & Co., Inc. Compositions ophtalmiques pour traiter une hypertension oculaire
EP1939175A1 (fr) 2005-09-27 2008-07-02 Shionogi&Co., Ltd. Dérivé sulfonamide ayant une activité antagoniste de récepteur pgd2
US20100016368A1 (en) 2008-07-15 2010-01-21 Li Chen Aminotetrahydroindazoloacetic acids
US20100016369A1 (en) 2008-07-15 2010-01-21 Li Chen Aminotetrahydroindazoloacetic acids
US20100041760A1 (en) 2008-08-15 2010-02-18 Jean-Baptiste Blanc Monoaryl aminotetralines
US20100041714A1 (en) 2008-08-15 2010-02-18 Jean-Baptiste Blanc Bi-aryl aminotetralines
US20100041713A1 (en) 2008-08-15 2010-02-18 Fariborz Firooznia Substituted aminotetralines
US20100125061A1 (en) 2008-11-17 2010-05-20 Fariborz Firooznia Naphthylacetic acids
US20100125058A1 (en) 2008-11-17 2010-05-20 Li Chen Naphthylacetic acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2263015T3 (es) * 2002-10-21 2006-12-01 Warner-Lambert Company Llc Derivados de tetrahidroquinolina como antagonistas de crth2.
EP1413306A1 (fr) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Dérivé de la tétrahydroquinoline en tant qu'antagonistes de CRTH2
EP1628532A2 (fr) * 2003-05-30 2006-03-01 Microbia, Inc. Procedes destines a la protection de la memoire et de la cognition
GB0518783D0 (en) * 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
EA200970590A1 (ru) * 2006-12-21 2009-12-30 Арджента Дискавери Лимитед Антагонисты crth2

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899529A (en) 1973-02-22 1975-08-12 Merck & Co Inc Aroyl substituted naphthalene acetic acids
US4443462A (en) 1979-08-06 1984-04-17 Merrell Dow Pharmaceuticals Inc. Antipsychotic 4-(naphthalenyloxy)piperidine derivatives
US4371537A (en) 1981-08-13 1983-02-01 The Dow Chemical Company Sulfur-substituted phenoxypyridines having antiviral activity
EP0242518A1 (fr) 1986-02-21 1987-10-28 Bayer Ag Cycloalcano[1,2-b]indole-sulfonamides
US4921998A (en) 1986-07-16 1990-05-01 Bayer Aktiengesellschaft Substituted amino-5,6,7,8-tetrahydronaphthyl-oxyacetic acids, processes for their preparation and their use as medicaments
US4868331A (en) 1986-07-16 1989-09-19 Bayer Aktiengesellschaft Substituted amino-5,6,7,8-tetrahydronaphthyl-oxyacetic acids, processes for their preparation and their use as medicaments
EP0253257A2 (fr) 1986-07-16 1988-01-20 Bayer Ag Acides amino-5,6,7,8-tétrahydronaphtyl-oxyacétiques substitués, procédé pour leur fabrication et leur utilisation comme médicaments
EP0405602A1 (fr) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. Dérivés zinciques de substances antiiflammatoires doués d'une activité thérapeutique améliorée
WO1992001675A2 (fr) 1990-07-24 1992-02-06 Rhone-Poulenc Rorer S.A. Composes bis-aryle bicycliques substitues ayant une activite antagoniste selective sur le leukotriene b4, leur preparation et utilisation dans des compositions pharmaceutiques
US5424481A (en) 1992-10-19 1995-06-13 Basf Aktiengesellschaft Preparation of methylsulfonylbenzoic acids
DE4411856A1 (de) 1993-04-06 1994-10-13 Kao Corp Keratinfaser-Behandlungszusammensetzung
EP0657422A1 (fr) 1993-12-09 1995-06-14 Ono Pharmaceutical Co., Ltd. Dérivés de l'acide naphtylacétique comme agonistes et antagonistes de PGEZ
WO2000016798A1 (fr) 1998-09-22 2000-03-30 Curtin University Of Technology Utilisation de composes non-peptidyliques pour le traitement d'affections liees a l'insuline
WO2003028755A1 (fr) 2001-09-28 2003-04-10 Intermune, Inc. Methode de traitement d'une infection par le virus de l'hepatite c chez des patients prealablement traites sans succes
EP1505061A1 (fr) 2002-05-16 2005-02-09 SHIONOGI & CO., LTD. Compose comprenant un antagonisme du recepteur de pdg2
US20070161698A1 (en) 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
US20050014749A1 (en) 2003-06-20 2005-01-20 Amgen Inc. Piperazine derivatives and methods of use
WO2005040114A1 (fr) 2003-10-14 2005-05-06 Oxagen Limited Composes presentant une activite antagoniste de crth2
WO2005054232A1 (fr) 2003-11-26 2005-06-16 Astrazeneca Ab Acide indole 1-acetique, et derives d'indazole et de benzimidazole utilises pour traiter les troubles respiratoires
US7226951B2 (en) 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
WO2006034418A2 (fr) 2004-09-21 2006-03-30 Athersys, Inc. Acides benzimidazole acetiques presentant un antagonisme du recepteur crth2 et utilisations associees
WO2006036664A1 (fr) 2004-09-23 2006-04-06 Amgen Inc. Sulfonamidopropionamides substitues et procedes d'utilisation
US20060154965A1 (en) 2004-12-21 2006-07-13 Harris Ralph N Iii Tetralin and indane derivatives and uses thereof
WO2006091674A1 (fr) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires
WO2007028132A2 (fr) 2005-09-01 2007-03-08 Eli Lilly And Company 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES SUBSTITUEES PAR UN HETEROCYCLE A LIAISON 6-N EN TANT QU'AGONISTES DE RECEPTEUR 5-HT2C
EP1939175A1 (fr) 2005-09-27 2008-07-02 Shionogi&Co., Ltd. Dérivé sulfonamide ayant une activité antagoniste de récepteur pgd2
WO2007146136A2 (fr) 2006-06-12 2007-12-21 Merck & Co., Inc. Compositions ophtalmiques pour traiter une hypertension oculaire
US20100016368A1 (en) 2008-07-15 2010-01-21 Li Chen Aminotetrahydroindazoloacetic acids
US20100016369A1 (en) 2008-07-15 2010-01-21 Li Chen Aminotetrahydroindazoloacetic acids
US20100041760A1 (en) 2008-08-15 2010-02-18 Jean-Baptiste Blanc Monoaryl aminotetralines
US20100041714A1 (en) 2008-08-15 2010-02-18 Jean-Baptiste Blanc Bi-aryl aminotetralines
US20100041713A1 (en) 2008-08-15 2010-02-18 Fariborz Firooznia Substituted aminotetralines
US20100125061A1 (en) 2008-11-17 2010-05-20 Fariborz Firooznia Naphthylacetic acids
US20100125058A1 (en) 2008-11-17 2010-05-20 Li Chen Naphthylacetic acids

Non-Patent Citations (40)

* Cited by examiner, † Cited by third party
Title
Arnold et al., Org. Lett, 6 (2004) 3005-3007.
Baldwin, K. P. et al., Synlett 11 (1993) 853.
Bargar, T. M. et al., J. Heterocyclic Chem. 22 (1985) 1583-1592.
Blizzard T. A. et al., Bioorg. Med. Chem. Lett. 14 (2004) 3861-3864.
Bloomer, J. L. et al., J. Org. Chem. 58 (1993) 7906-7912.
Boger, D. L. et al., J. Org. Chem. 61 (1996) 4894-4912.
Chan W. K., et al., J. Med. Chem. 39 (1996) 3756-3768.
Cosmi et al., Eur J. Immunol 30, 2972-2979, 2000.
Database Registry (online) RN 1026178-75-5 (2008) XP002547292.
Feixas J et al, "Naphthalene Derivatives; a New Series of Selective Cycloxygenase-2 Inhibitors" Bioorganic & Medicinal Chemistry Letters, 11:20 (2001) 2687-2690 XP0029995309.
Feixas Jet Al, "Naphthalene Derivatives; a New Series of Selective Cycloxygenase-2 Inhibitors" Bioorganic & Medicinal Chemistry Letters, 11:20 (2001) 2687-2690. *
Fuganti, C. et al., J. Chem. Res (S) 1998, 638-639.
Gervais et al., J Allergy Clin Immunol 108: 982-988 (2001).
Hayashi, N. et al., Org. Lett. 7 (2005) 3093-3096.
Hayashi, N., et al., Org. Lett. 6 (2004) 4981-4983.
Hirai et al., J Exp Med 193: 255-261, 2001.
Huang et al., Hum Mol Genet 13, 2691-2697, 2004.
Kim, M. et al., J. Org. Chem. 69 (2004) 6945-6948.
Kostenis et al., "Emerging roles of DP and CRTH2 in allergic inflammation" Science Direct, Trends in Molecule Medicine vol. 12 No. 4, Apr. 2006, pp. 148-158, Elsevier.
Kozhinov, D. V., et al., J. Org. Chem. 69 (2004) 1378-1379.
Lee et al., Tetrahedron Lett., 32 (1991) 5255.
Letter re: Thailand Office Action for Thai Patent Appl. No. 0901005108 ( Jul. 11, 2011).
Li J. et al., Bioorg. Med. Chem. 13 (2005) 1805-1809.
Liu, J., et al., Org. Lett. 4 (2002) 3521-3524.
Moseley, J. D. et al., Tetrahedron 62 (2006) 4685-4689.
Nagata et al., FEBS Lett 459: 195-199, 1999.
Pettipher et al., "Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases." Nature Reviews Drug Discovery, vol. 6 (Apr. 2007) pp. 313-325, Nature Publishing Group.
Schön, U. et al., Tetrahedron Lett. 46 (2005) 7111-7115.
Staas, D. D. et al., Bioorg. Med. Chem. 14 (2006) 6900.
Testaferri, L. et al., Tetrahedron 41 (1985) 1373-1384.
Thibault, M. E. et al., J. Org. Chem. 68 (2003), 8373-8378.
Ulven et al., "Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation" Current Topics in Medicinal Chemistry 6:13 (2006) 1427-1444 XP008104082.
Uno, H., et al., J. Chem. Soc., Perkin Trans. 1, 2001, 229.
Wallace, D. J. et al., Tetrahedron Lett. 43 (2002) 6987-6990.
Wu G., et al., Synthesis 11 (2003) 1657-1660.
Xue et al., J Immunol 175: 6531-6536.
Xue, L. et al., Journal of Immunology 175:6531-6536 ( 2005).
Yoshimura-Uchiyama et al., Clin Exp Allergy 34:1283-1290.
Yoshimura-Uchiyama et al., Clin. Exp. Allergy 35:1283-1290 ( 2004).
Zupan M. et al., Bull. Chem. Soc. Jpn., 68 (1995) 1655-1660.

Also Published As

Publication number Publication date
US20100137250A1 (en) 2010-06-03
MX2011005200A (es) 2011-06-01
BRPI0921254A2 (pt) 2018-10-23
CN102216249A (zh) 2011-10-12
ZA201102525B (en) 2012-09-26
IL212120A0 (en) 2011-06-30
TW201022197A (en) 2010-06-16
RU2011124149A (ru) 2012-12-27
EP2346807A1 (fr) 2011-07-27
KR20110071122A (ko) 2011-06-28
CA2740864A1 (fr) 2010-05-20
WO2010055005A1 (fr) 2010-05-20
AR074353A1 (es) 2011-01-12
AU2009315713A1 (en) 2010-05-20
PE20110710A1 (es) 2011-10-13
TWI385145B (zh) 2013-02-11
JP2012508715A (ja) 2012-04-12

Similar Documents

Publication Publication Date Title
US8124629B2 (en) Naphthylacetic acids
US8642629B2 (en) Naphthylacetic acids
US8263656B2 (en) Substituted aminotetralines
US8138208B2 (en) Aminotetrahydroindazoloacetic acids
US8268870B2 (en) Aminotetrahydroindazoloacetic acids
JP2006522118A (ja) 新規化合物
US9000044B2 (en) Substituted naphthylacetic acids
US8470884B2 (en) Alkenyl naphthylacetic acids

Legal Events

Date Code Title Description
CC Certificate of correction
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20160228